Hydromorphone injection recalled for incorrect or missing labeling information
STAQ Pharma is recalling Hydromorphone HCL PF injections due to incorrect or missing lot numbers and expiration dates on product labels. Affected product was distributed nationwide.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is a Class III FDA drug recall involving a labeling error (missing or incorrect lot and expiration date information). No illnesses, injuries, or deaths have been reported. Per the severity rubric, minor labeling errors are classified as Moderate severity.
Plain-English summary
STAQ Pharma, Inc. is recalling Hydromorphone HCL PF, 10mg/50 mL (0.2mg/mL) in NACL, Injection for IV use, 50 mL Syringe due to labeling defects involving incorrect or missing lot numbers and expiration dates.
The recalled product, lot number 25104595A with expiration date December 27, 2025, was distributed nationwide in the United States. The labeling issue affects the product's identification and safety information.
Healthcare providers and patients who have received this product should verify the labeling information, including the lot number and expiration date. Products with incorrect or missing labeling information should not be used.
Consumers or healthcare facilities in possession of the recalled product should contact STAQ Pharma, Inc. for further instructions.
The recalled product
- Product
- Hydromorphone HCL PF, 10mg/50 mL (0.2mg/mL) in NACL, Injection for IV use, 50 mL Syringe, STAQ Pharma Inc., 14135 E 42nd Ave, Denver, Colorado, NDC 73177-0104-05.
- Manufacturer
- STAQ Pharma, Inc.
- Category
- Drug
- Hazard
- mis-labeling
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: 25104595A
- Expiry: 27DEC2025.
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27